Copyright © 2024 广州源井生物科技有限公司 版权所有
粤ICP备19080093号
Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer
High Throughput Confined Migration Microfluidic Device for Drug Screening
Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targets in Thyroid Cancer
IF=5.0
The Journal of clinical endocrinology and metabolism